CTOs on the Move


 
Lupin is a USD 2.55 billion innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.lupin.com
  • Harborplace Tower 111 South Calvert Street 21st Floor
    Baltimore, MD USA 21202
  • Phone: 410.576.2000

Executives

Name Title Contact Details
Marc Bowman
Associate Director of Information Technology Profile

Similar Companies

Stiefel, a GSK Company

Stiefel, a GSK Company is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Umoja Biopharma

Umoja is developing a new approach to cancer therapy that retools a patient`s immune system in vivo, enhancing the body`s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.

Sanofi

3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

Afecta Pharmaceuticals

Afecta Pharmaceuticals is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.